At September 30, 2024, ProQR held cash and cash equivalents of EUR 89.4 million, compared to EUR 118.9 million cash and cash equivalents at December 31, 2023. Net cash used in operating activities during the three-month period ended September 30, 2024 was EUR 5.7 million, compared to EUR 7.5 million used for the same period last year. During the first three quarters of 2024, the Company achieved certain milestones in the collaboration agreement with Eli Lilly amounting to $5.5 million. In October, the Company closed an underwritten public offering of 18,000,000 ordinary shares and a concurrent private placement of 3,523,538 ordinary shares with Eli Lilly, as well as exercise of the underwriter’s option for 1,940,072 additional shares for gross proceeds totaling approximately $82.1 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRQR:
- PRQR Earnings this Week: How Will it Perform?
- Trade Desk downgraded, First Solar upgraded: Wall Street’s top analyst calls
- ProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond James
- ProQR Announces Major Share Offering Agreement
- Largest borrow rate increases among liquid names
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
